Renaissance Technologies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-611,300
| Closed | -$972K | – | 4107 |
|
|
2024
Q1 | $972K | Sell |
611,300
-145,592
| -19% | -$216K | ﹤0.01% | 2507 |
|
|
2023
Q4 | $650K | Buy |
756,892
+234,565
| +45% | +$206K | ﹤0.01% | 2655 |
|
|
2023
Q3 | $559K | Buy |
522,327
+269,727
| +107% | +$558K | ﹤0.01% | 2659 |
|
|
2023
Q2 | $654K | Sell |
252,600
-76,900
| -23% | -$274K | ﹤0.01% | 2730 |
|
|
2023
Q1 | $1.34M | Sell |
329,500
-14,000
| -4% | -$64.7K | ﹤0.01% | 2271 |
|
|
2022
Q4 | $1.72M | Buy |
343,500
+69,300
| +25% | +$434K | ﹤0.01% | 2166 |
|
|
2022
Q3 | $3.59M | Sell |
274,200
-64,168
| -19% | -$972K | 0.01% | 1645 |
|
|
2022
Q2 | $4.34M | Buy |
338,368
+182,668
| +117% | +$2.53M | 0.01% | 1669 |
|
|
2022
Q1 | $2.37M | Buy |
155,700
+81,000
| +108% | +$1.26M | ﹤0.01% | 2110 |
|
|
2021
Q4 | $1.32M | Buy |
74,700
+61,400
| +462% | +$1.18M | ﹤0.01% | 2454 |
|
|
2021
Q3 | $280K | Buy |
+13,300
| New | +$293K | ﹤0.01% | 3103 |
|
|
2020
Q4 | – | Sell |
-82,200
| Closed | -$1.31M | – | 3799 |
|
|
2020
Q3 | $1.31M | Sell |
82,200
-86,800
| -51% | -$1.58M | ﹤0.01% | 2367 |
|
|
2020
Q2 | $3.34M | Buy |
169,000
+19,900
| +13% | +$380K | ﹤0.01% | 1873 |
|
|
2020
Q1 | $1.84M | Buy |
+149,100
| New | +$2.43M | ﹤0.01% | 2093 |
|
Renaissance Technologies's NGM Position: Q2 2024 in Review
Renaissance Technologies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 611,300 shares — an estimated $972K sold.
Renaissance Technologies first reported a position in NGM in Q1 2020 and held it in 14 quarters. The position peaked at $4.34M in Q2 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Renaissance Technologies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Renaissance Technologies sold 611,300 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $972K.
- Renaissance Technologies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
- Renaissance Technologies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4.34M in Q2 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.